Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Marker Therapeutics reports Q1 EPS , consensus (14c) » 16:25
05/12/21
05/12
16:25
05/12/21
16:25
MRKR

Marker Therapeutics

$2.17 /

-0.175 (-7.48%)

At March 31, Marker had…

At March 31, Marker had cash and cash equivalents of $64.5M. The company believes that its existing cash and cash equivalents will fund its operating expenses and capital expenditure requirements into Q1 2023. "We had a productive first quarter supported by our recently completed financing, strengthening our overall cash position and enabling continued growth and expansion of our Multi-TAA pipeline," said CEO Peter Hoang. "In addition, we continue to make strong progress on both the clinical and manufacturing fronts. In March, we dosed the first patient in the safety lead-in portion of our Phase 2 trial in post-transplant acute myeloid leukemia, or AML, and continue to activate clinical sites. In parallel, we continue to optimize the MT-401 cell therapy manufacturing process, which we believe could result in an increase in the number of T cells available for patient administration-among other benefits-as we prepare to operationalize our new in-house cGMP facility in the first half of the year."

ShowHide Related Items >><<
MRKR Marker Therapeutics
$2.17 /

-0.175 (-7.48%)

MRKR Marker Therapeutics
$2.17 /

-0.175 (-7.48%)

03/25/21 Piper Sandler
Marker Therapeutics initiated with an Overweight at Piper Sandler
03/19/21
Fly Intel: Top five analyst initiations
03/18/21 Cantor Fitzgerald
Cantor Fitzgerald starts 'undervalued' Marker Therapeutics at Overweight
03/18/21 Cantor Fitzgerald
Marker Therapeutics initiated with an Overweight at Cantor Fitzgerald
  • 12
    Mar
MRKR Marker Therapeutics
$2.17 /

-0.175 (-7.48%)

Hot Stocks
Marker Therapeutics to present mTAA-specific T cell manufacturing data » 19:49
04/27/21
04/27
19:49
04/27/21
19:49
MRKR

Marker Therapeutics

$2.46 /

-0.07 (-2.77%)

Marker Therapeutics…

Marker Therapeutics announced that it will present data detailing a new robotics technology to aid in multi-tumor-associated antigen (mTAA)-specific T cell therapy manufacturing at the upcoming American Society of Gene & Cell Therapy Annual Meeting, taking place virtually May 11-14, 2021. The data will be presented by lead author Anastasiya Smith, Ph.D. The presentation details how the robotic assistant prototype, co-designed by Marker Therapeutics and ABB Robotics, could in the future be integrated in a standard biosafety cabinet to collaborate with a human operator during mTAA-specific T cell manufacturing. The researchers found that the robotic assistant prototype was more precise and accurate than human operators in pipetting liquid and was more consistent in the number of cycles performed over a 1-hour test period, while the human operator's performance deteriorated over time. The authors conclude that the future combination of process simplification with robotic automation may be able to address some of the challenges associated with cell therapy and make this therapy readily available to a larger patient population.

ShowHide Related Items >><<
MRKR Marker Therapeutics
$2.46 /

-0.07 (-2.77%)

MRKR Marker Therapeutics
$2.46 /

-0.07 (-2.77%)

03/25/21 Piper Sandler
Marker Therapeutics initiated with an Overweight at Piper Sandler
03/19/21
Fly Intel: Top five analyst initiations
03/18/21 Cantor Fitzgerald
Cantor Fitzgerald starts 'undervalued' Marker Therapeutics at Overweight
03/18/21 Cantor Fitzgerald
Marker Therapeutics initiated with an Overweight at Cantor Fitzgerald
MRKR Marker Therapeutics
$2.46 /

-0.07 (-2.77%)

  • 12
    Mar
MRKR Marker Therapeutics
$2.46 /

-0.07 (-2.77%)

Over a quarter ago
Initiation
Marker Therapeutics initiated with an Overweight at Piper Sandler » 04:55
03/25/21
03/25
04:55
03/25/21
04:55
MRKR

Marker Therapeutics

$2.33 /

-0.24 (-9.34%)

Piper Sandler analyst…

Piper Sandler analyst Joseph Catanzaro initiated coverage of Marker Therapeutics with an Overweight rating and $6 price target. The analyst views the company's MultiTAA platform as a "highly differentiated" T-cell therapy that offers "multiple potential distinct advantages" at both clinical efficacy and safety, as well as manufacturability. With a potentially registrational Phase II acute myeloid leukemia trial now enrolling, Catanzaro sees "significant opportunity" for Marker shares to appreciate as the MultiTAA platform is advanced through the clinic.

ShowHide Related Items >><<
MRKR Marker Therapeutics
$2.33 /

-0.24 (-9.34%)

MRKR Marker Therapeutics
$2.33 /

-0.24 (-9.34%)

03/19/21
Fly Intel: Top five analyst initiations
03/18/21 Cantor Fitzgerald
Cantor Fitzgerald starts 'undervalued' Marker Therapeutics at Overweight
03/18/21 Cantor Fitzgerald
Marker Therapeutics initiated with an Overweight at Cantor Fitzgerald
01/05/21 Oppenheimer
Marker hits 'important milestone' with end of clinical hold, says Oppenheimer
MRKR Marker Therapeutics
$2.33 /

-0.24 (-9.34%)

  • 12
    Mar
MRKR Marker Therapeutics
$2.33 /

-0.24 (-9.34%)

Initiation
Fly Intel: Top five analyst initiations » 09:30
03/19/21
03/19
09:30
03/19/21
09:30
BYND

Beyond Meat

$133.80 /

-5.47 (-3.93%)

, NEBC

Nebula Caravel Acquisition

$9.98 /

+0.03 (+0.30%)

, APD

Air Products

$269.08 /

-1.445 (-0.53%)

, MRKR

Marker Therapeutics

$1.81 /

-0.07 (-3.73%)

, AEVA

Aeva Technologies

$13.12 /

-1.03 (-7.28%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Beyond Meat (BYND) initiated at Stephens with an Overweight rating. 2. Rover (NEBC) initiated at DA Davidson with a Buy rating. 3. Air Products (APD) initiated with an Outperform rating at Cowen. 4. Marker Therapeutics (MRKR) initiated with an Overweight rating at Cantor Fitzgerald. 5. Aeva Technologies (AEVA) started with an Outperform rating at Oppenheimer. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
NEBC Nebula Caravel Acquisition
$9.98 /

+0.03 (+0.30%)

MRKR Marker Therapeutics
$1.81 /

-0.07 (-3.73%)

BYND Beyond Meat
$133.80 /

-5.47 (-3.93%)

APD Air Products
$269.08 /

-1.445 (-0.53%)

AEVA Aeva Technologies
$13.12 /

-1.03 (-7.28%)

BYND Beyond Meat
$133.80 /

-5.47 (-3.93%)

03/18/21 Stephens
Stephens starts Beyond Meat at buy with alternative protein 'going mainstream'
03/18/21 Stephens
Beyond Meat initiated with an Overweight at Stephens
03/16/21 JPMorgan
Beyond Meat price target lowered to $91 from $94 at JPMorgan
03/02/21
Fly Intel: Top five analyst upgrades
NEBC Nebula Caravel Acquisition
$9.98 /

+0.03 (+0.30%)

03/19/21 DA Davidson
Rover initiated with a Buy at DA Davidson amid COVID-related tailwinds
APD Air Products
$269.08 /

-1.445 (-0.53%)

03/18/21 Cowen
Cowen starts Air Products at Outperform, names top pick in gas
03/18/21 Cowen
Air Products initiated with an Outperform at Cowen
03/15/21 Credit Suisse
Air Products assumed with an Outperform at Credit Suisse
02/08/21 BofA
Air Products upgraded to Buy from Neutral at BofA
MRKR Marker Therapeutics
$1.81 /

-0.07 (-3.73%)

03/18/21 Cantor Fitzgerald
Cantor Fitzgerald starts 'undervalued' Marker Therapeutics at Overweight
03/18/21 Cantor Fitzgerald
Marker Therapeutics initiated with an Overweight at Cantor Fitzgerald
01/05/21 Oppenheimer
Marker hits 'important milestone' with end of clinical hold, says Oppenheimer
05/12/20
Fly Intel: Top five analyst downgrades
AEVA Aeva Technologies
$13.12 /

-1.03 (-7.28%)

03/18/21 Oppenheimer
Oppenheimer starts Aeva Technologies at Outperform with $20 price target
03/18/21 Oppenheimer
Aeva Technologies initiated with an Outperform at Oppenheimer
03/18/21
Fly Intel: Top five analyst initiations
03/18/21 Piper Sandler
Aeva Technologies initiated with an Overweight at Piper Sandler
MRKR Marker Therapeutics
$1.81 /

-0.07 (-3.73%)

BYND Beyond Meat
$133.80 /

-5.47 (-3.93%)

APD Air Products
$269.08 /

-1.445 (-0.53%)

  • 12
    Mar
BYND Beyond Meat
$133.80 /

-5.47 (-3.93%)

MRKR Marker Therapeutics
$1.81 /

-0.07 (-3.73%)

BYND Beyond Meat
$133.80 /

-5.47 (-3.93%)

APD Air Products
$269.08 /

-1.445 (-0.53%)

BYND Beyond Meat
$133.80 /

-5.47 (-3.93%)

AEVA Aeva Technologies
$13.12 /

-1.03 (-7.28%)

On The Fly
Fly Intel: Pre-market Movers » 09:01
03/19/21
03/19
09:01
03/19/21
09:01
NKE

Nike

$143.33 /

-1.45 (-1.00%)

, FDX

FedEx

$263.98 /

-1.81 (-0.68%)

, IDRA

Idera Pharmaceuticals

$5.21 /

+0.035 (+0.68%)

, MRKR

Marker Therapeutics

$1.81 /

-0.07 (-3.73%)

, SKLZ

Skillz

$26.75 /

-2.55 (-8.70%)

, FSR

Fisker

$20.00 /

-1.59 (-7.36%)

Check out this morning's…

ShowHide Related Items >><<
SKLZ Skillz
$26.75 /

-2.55 (-8.70%)

NKE Nike
$143.33 /

-1.45 (-1.00%)

MRKR Marker Therapeutics
$1.81 /

-0.07 (-3.73%)

IDRA Idera Pharmaceuticals
$5.21 /

+0.035 (+0.68%)

FSR Fisker
$20.00 /

-1.59 (-7.36%)

FDX FedEx
$263.98 /

-1.81 (-0.68%)

NKE Nike
$143.33 /

-1.45 (-1.00%)

03/19/21 BTIG
BTIG says Nike should make up revenue lost to supply chain issues
03/19/21 UBS
UBS sees upside in Nike guidance, keeps Buy rating after Q3 results
03/19/21 Citi
Nike brand 'strong as ever' despite Q3 sales miss, says Citi
03/19/21 Stifel
Stifel says focus on Nike's demand strength, not temporary supply challenges
FDX FedEx
$263.98 /

-1.81 (-0.68%)

03/19/21 JPMorgan
FedEx shares should outperform on Ground beat, says JPMorgan
03/19/21 Baird
FedEx core execution solid despite winter storm challenges, says Baird
03/19/21 Raymond James
FedEx price target raised to $310 from $305 at Raymond James
03/19/21 Goldman Sachs
FedEx price target raised to $365 from $356 at Goldman Sachs
IDRA Idera Pharmaceuticals
$5.21 /

+0.035 (+0.68%)

03/19/21
Fly Intel: Top five analyst downgrades
03/19/21 Jefferies
Checkmate Pharmaceuticals price target lowered to $19 from $23 at Jefferies
03/19/21 Wedbush
Idera Pharmaceuticals downgraded to Neutral from Outperform at Wedbush
03/19/21 JPMorgan
Idera Pharmaceuticals downgraded to Neutral after trial miss at JPMorgan
MRKR Marker Therapeutics
$1.81 /

-0.07 (-3.73%)

03/19/21
Fly Intel: Top five analyst initiations
03/18/21 Cantor Fitzgerald
Cantor Fitzgerald starts 'undervalued' Marker Therapeutics at Overweight
03/18/21 Cantor Fitzgerald
Marker Therapeutics initiated with an Overweight at Cantor Fitzgerald
01/05/21 Oppenheimer
Marker hits 'important milestone' with end of clinical hold, says Oppenheimer
SKLZ Skillz
$26.75 /

-2.55 (-8.70%)

03/11/21 Canaccord
Skillz price target raised to $33 from $32 at Canaccord
02/25/21
Fly Intel: Top five analyst initiations
02/25/21 UBS
Skillz initiated with a Neutral at UBS
01/19/21 Canaccord
Skillz platform accelerates, Canacord initiates with Buy
FSR Fisker
$20.00 /

-1.59 (-7.36%)

03/10/21 Citi
Fisker price target raised to $31 from $26 at Citi
03/03/21 Wolfe Research
Wolfe upgrades Fisker, says Foxconn deal 'changed the narrative'
03/03/21 Wolfe Research
Fisker upgraded to Peer Perform from Underperform at Wolfe Research
02/26/21 Morgan Stanley
Fisker price target raised to $40 from $27 at Morgan Stanley
SKLZ Skillz
$26.75 /

-2.55 (-8.70%)

NKE Nike
$143.33 /

-1.45 (-1.00%)

MRKR Marker Therapeutics
$1.81 /

-0.07 (-3.73%)

IDRA Idera Pharmaceuticals
$5.21 /

+0.035 (+0.68%)

FSR Fisker
$20.00 /

-1.59 (-7.36%)

FDX FedEx
$263.98 /

-1.81 (-0.68%)

  • 19
    Mar
  • 12
    Mar
SKLZ Skillz
$26.75 /

-2.55 (-8.70%)

NKE Nike
$143.33 /

-1.45 (-1.00%)

FSR Fisker
$20.00 /

-1.59 (-7.36%)

FDX FedEx
$263.98 /

-1.81 (-0.68%)

SKLZ Skillz
$26.75 /

-2.55 (-8.70%)

NKE Nike
$143.33 /

-1.45 (-1.00%)

MRKR Marker Therapeutics
$1.81 /

-0.07 (-3.73%)

FSR Fisker
$20.00 /

-1.59 (-7.36%)

FDX FedEx
$263.98 /

-1.81 (-0.68%)

SKLZ Skillz
$26.75 /

-2.55 (-8.70%)

NKE Nike
$143.33 /

-1.45 (-1.00%)

FSR Fisker
$20.00 /

-1.59 (-7.36%)

FDX FedEx
$263.98 /

-1.81 (-0.68%)

Hot Stocks
Marker Therapeutics up 20% at $2.17 per share after insider transaction  16:54
03/18/21
03/18
16:54
03/18/21
16:54
MRKR

Marker Therapeutics

$1.81 /

-0.07 (-3.73%)

 
ShowHide Related Items >><<
MRKR Marker Therapeutics
$1.81 /

-0.07 (-3.73%)

MRKR Marker Therapeutics
$1.81 /

-0.07 (-3.73%)

03/18/21 Cantor Fitzgerald
Cantor Fitzgerald starts 'undervalued' Marker Therapeutics at Overweight
03/18/21 Cantor Fitzgerald
Marker Therapeutics initiated with an Overweight at Cantor Fitzgerald
01/05/21 Oppenheimer
Marker hits 'important milestone' with end of clinical hold, says Oppenheimer
05/12/20
Fly Intel: Top five analyst downgrades
MRKR Marker Therapeutics
$1.81 /

-0.07 (-3.73%)

  • 12
    Mar
MRKR Marker Therapeutics
$1.81 /

-0.07 (-3.73%)

Hot Stocks
Marker Therapeutics director buys 1.7M shares of common stock » 16:49
03/18/21
03/18
16:49
03/18/21
16:49
MRKR

Marker Therapeutics

$1.81 /

-0.07 (-3.73%)

In a regulatory filing,…

In a regulatory filing, Marker Therapeutics disclosed that its director John Wilson bought 1.7M shares on March 16th in a total transaction size of $3.0M, boosting his stake by 28%.

ShowHide Related Items >><<
MRKR Marker Therapeutics
$1.81 /

-0.07 (-3.73%)

MRKR Marker Therapeutics
$1.81 /

-0.07 (-3.73%)

03/18/21 Cantor Fitzgerald
Cantor Fitzgerald starts 'undervalued' Marker Therapeutics at Overweight
03/18/21 Cantor Fitzgerald
Marker Therapeutics initiated with an Overweight at Cantor Fitzgerald
01/05/21 Oppenheimer
Marker hits 'important milestone' with end of clinical hold, says Oppenheimer
05/12/20
Fly Intel: Top five analyst downgrades
MRKR Marker Therapeutics
$1.81 /

-0.07 (-3.73%)

  • 12
    Mar
MRKR Marker Therapeutics
$1.81 /

-0.07 (-3.73%)

Initiation
Cantor Fitzgerald starts 'undervalued' Marker Therapeutics at Overweight » 16:17
03/18/21
03/18
16:17
03/18/21
16:17
MRKR

Marker Therapeutics

$1.81 /

-0.07 (-3.73%)

As previously reported,…

As previously reported, Cantor Fitzgerald analyst Kristen Kluska initiated coverage of Marker Therapeutics with an Overweight rating and $6 price target. The company is focusing on novel T-cell immunotherapies based on the Multiple Tumor-Associated Antigen, or "MultiTAA," therapy platform and she believes shares are undervalued given the potential for its technology to target multiple antigens, allow for a safer profile, and increase durability, Kluska tells investors.

ShowHide Related Items >><<
MRKR Marker Therapeutics
$1.81 /

-0.07 (-3.73%)

MRKR Marker Therapeutics
$1.81 /

-0.07 (-3.73%)

03/18/21 Cantor Fitzgerald
Marker Therapeutics initiated with an Overweight at Cantor Fitzgerald
01/05/21 Oppenheimer
Marker hits 'important milestone' with end of clinical hold, says Oppenheimer
05/12/20
Fly Intel: Top five analyst downgrades
05/12/20 Piper Sandler
Marker Therapeutics downgraded to Neutral from Overweight at Piper Sandler
MRKR Marker Therapeutics
$1.81 /

-0.07 (-3.73%)

  • 12
    Mar
MRKR Marker Therapeutics
$1.81 /

-0.07 (-3.73%)

Initiation
Marker Therapeutics initiated with an Overweight at Cantor Fitzgerald » 16:04
03/18/21
03/18
16:04
03/18/21
16:04
MRKR

Marker Therapeutics

$1.79 /

-0.09 (-4.80%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Kristen Kluska initiated coverage of Marker Therapeutics with an Overweight rating and $6 price target.

ShowHide Related Items >><<
MRKR Marker Therapeutics
$1.79 /

-0.09 (-4.80%)

MRKR Marker Therapeutics
$1.79 /

-0.09 (-4.80%)

01/05/21 Oppenheimer
Marker hits 'important milestone' with end of clinical hold, says Oppenheimer
05/12/20
Fly Intel: Top five analyst downgrades
05/12/20 Piper Sandler
Marker Therapeutics downgraded to Neutral from Overweight at Piper Sandler
MRKR Marker Therapeutics
$1.79 /

-0.09 (-4.80%)

  • 12
    Mar
MRKR Marker Therapeutics
$1.79 /

-0.09 (-4.80%)

On The Fly
Fly Intel: Pre-market Movers » 08:53
03/12/21
03/12
08:53
03/12/21
08:53
LB

L Brands

$55.83 /

+1.1 (+2.01%)

, CFRX

ContraFect

$6.32 /

+1.25 (+24.65%)

, NVAX

Novavax

$187.62 /

+15.04 (+8.71%)

, WISA

Summit Wireless

$3.50 /

+0.31 (+9.72%)

, ITRM

Iterum Therapeutics

$1.60 /

+0.23 (+16.79%)

, DSSI

Diamond S Shipping

$9.39 /

+0.1 (+1.08%)

, OCUL

Ocular Therapeutix

$20.26 /

+0.58 (+2.95%)

, POSH

Poshmark

$59.28 /

+7.97 (+15.53%)

, RIDE

Lordstown Motors

$17.70 /

+0.705 (+4.15%)

, MRKR

Marker Therapeutics

$2.52 /

+0.01 (+0.40%)

, POWW

AMMO

$6.75 /

+0.45 (+7.14%)

, DS

Drive Shack

$2.66 /

+0.1 (+3.91%)

Check out this morning's…

ShowHide Related Items >><<
RIDE Lordstown Motors
$17.70 /

+0.705 (+4.15%)

POWW AMMO
$6.75 /

+0.45 (+7.14%)

POSH Poshmark
$59.28 /

+7.97 (+15.53%)

OCUL Ocular Therapeutix
$20.26 /

+0.58 (+2.95%)

NVAX Novavax
$187.62 /

+15.04 (+8.71%)

MRKR Marker Therapeutics
$2.52 /

+0.01 (+0.40%)

LB L Brands
$55.83 /

+1.1 (+2.01%)

ITRM Iterum Therapeutics
$1.60 /

+0.23 (+16.79%)

DSSI Diamond S Shipping
$9.39 /

+0.1 (+1.08%)

DS Drive Shack
$2.66 /

+0.1 (+3.91%)

CFRX ContraFect
$6.32 /

+1.25 (+24.65%)

LB L Brands
$55.83 /

+1.1 (+2.01%)

02/26/21
Fly Intel: Top five analyst upgrades
02/26/21 Citi
L Brands upgraded to Neutral from Sell at Citi
02/26/21 Morgan Stanley
Morgan Stanley upgrades L Brands on improved post-COVID profitability
02/26/21 KeyBanc
L Brands price target raised to $64 from $59 at KeyBanc
CFRX ContraFect
$6.32 /

+1.25 (+24.65%)

06/09/20
Fly Intel: Top five analyst initiations
06/09/20 Mizuho
ContraFect initiated with a Buy at Mizuho
06/08/20 Cantor Fitzgerald
ContraFect initiated with an Overweight at Cantor Fitzgerald
NVAX Novavax
$187.62 /

+15.04 (+8.71%)

03/12/21 H.C. Wainwright
Novavax price target raised to $317 from $207 at H.C. Wainwright
02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/22/21 Cantor Fitzgerald
Cantor says PREVENT-19 gives Novavax potential for differentiated analyses
02/22/21 B. Riley
B. Riley reiterates Buy rating on Novavax as PREVENT-19 enrollment wraps up
WISA Summit Wireless
$3.50 /

+0.31 (+9.72%)

01/13/21 H.C. Wainwright
Summit Wireless price target raised to $5.50 from $3.50 at H.C. Wainwright
12/14/20 H.C. Wainwright
Summit Wireless initiated with a Buy at H.C. Wainwright
10/01/20
Fly Intel: Top five analyst initiations
10/01/20 Maxim
Summit Wireless initiated with a Buy at Maxim
ITRM Iterum Therapeutics
$1.60 /

+0.23 (+16.79%)

12/24/20 H.C. Wainwright
Iterum CSO resignation 'somewhat troubling,' says H.C. Wainwright
06/16/20 H.C. Wainwright
Iterum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
06/02/20 RBC Capital
Iterum Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
DSSI Diamond S Shipping
$9.39 /

+0.1 (+1.08%)

01/29/21 Jefferies
Diamond S Shipping price target lowered to $10 from $11 at Jefferies
07/15/20 B. Riley
Diamond S Shipping price target lowered to $21 from $25 at B. Riley FBR
03/30/20 Fearnley
Diamond S Shipping downgraded to Hold from Buy at Fearnley
OCUL Ocular Therapeutix
$20.26 /

+0.58 (+2.95%)

02/12/21 Piper Sandler
Ocular Therapeutix to update on OTX-TKI's Phase I wAMD, says Piper Sandler
12/30/20 JMP Securities
Ocular Therapeutix price target raised to $30 from $20 at JMP Securities
12/28/20
Fly Intel: Top five analyst calls
12/28/20 H.C. Wainwright
Ocular Therapeutix downgraded to Neutral from Buy at H.C. Wainwright
POSH Poshmark
$59.28 /

+7.97 (+15.53%)

03/12/21 Raymond James
Poshmark price target lowered to $68 from $83 at Raymond James
03/12/21 Cowen
Poshmark price target lowered to $70 from $88 at Cowen
02/22/21 Evercore ISI
Evercore upgrades Foot Locker to Outperform on 'cemented' sneaker position
02/08/21
Fly Intel: Top five analyst initiations
RIDE Lordstown Motors
$17.70 /

+0.705 (+4.15%)

02/24/21 Oppenheimer
Opco downgrades Workhorse after Postal Service snub despite backlog
02/11/21 Morgan Stanley
Lordstown Motors initiated with an Underweight at Morgan Stanley
01/29/21 Wolfe Research
Wolfe upgrades Lordstown Motors to Peer Perform, says 'narrative has changed'
01/29/21 Wolfe Research
Lordstown Motors upgraded to Peer Perform from Underperform at Wolfe Research
MRKR Marker Therapeutics
$2.52 /

+0.01 (+0.40%)

01/05/21 Oppenheimer
Marker hits 'important milestone' with end of clinical hold, says Oppenheimer
05/12/20
Fly Intel: Top five analyst downgrades
05/12/20 Piper Sandler
Marker Therapeutics downgraded to Neutral from Overweight at Piper Sandler
POWW AMMO
$6.75 /

+0.45 (+7.14%)

DS Drive Shack
$2.66 /

+0.1 (+3.91%)

12/17/20 B. Riley
Drive Shack price target raised to $5.50 from $4 at B. Riley Securities
12/09/20 B. Riley
Drive Shack shares can nearly double from current levels, says at B. Riley
06/01/20
Fly Intel: Top five analyst initiations
06/01/20 B. Riley
B. Riley FBR starts Drive Shack at Buy on 'eatertainment' concept plans
WISA Summit Wireless
$3.50 /

+0.31 (+9.72%)

RIDE Lordstown Motors
$17.70 /

+0.705 (+4.15%)

POWW AMMO
$6.75 /

+0.45 (+7.14%)

POSH Poshmark
$59.28 /

+7.97 (+15.53%)

OCUL Ocular Therapeutix
$20.26 /

+0.58 (+2.95%)

NVAX Novavax
$187.62 /

+15.04 (+8.71%)

MRKR Marker Therapeutics
$2.52 /

+0.01 (+0.40%)

LB L Brands
$55.83 /

+1.1 (+2.01%)

ITRM Iterum Therapeutics
$1.60 /

+0.23 (+16.79%)

DSSI Diamond S Shipping
$9.39 /

+0.1 (+1.08%)

DS Drive Shack
$2.66 /

+0.1 (+3.91%)

CFRX ContraFect
$6.32 /

+1.25 (+24.65%)

  • 12
    Mar
  • 12
    Mar
  • 29
    Jan
  • 14
    Jan
  • 16
    Dec
  • 01
    Dec
  • 14
    Oct
  • 22
    May
  • 20
    May
RIDE Lordstown Motors
$17.70 /

+0.705 (+4.15%)

NVAX Novavax
$187.62 /

+15.04 (+8.71%)

LB L Brands
$55.83 /

+1.1 (+2.01%)

WISA Summit Wireless
$3.50 /

+0.31 (+9.72%)

RIDE Lordstown Motors
$17.70 /

+0.705 (+4.15%)

POSH Poshmark
$59.28 /

+7.97 (+15.53%)

OCUL Ocular Therapeutix
$20.26 /

+0.58 (+2.95%)

NVAX Novavax
$187.62 /

+15.04 (+8.71%)

LB L Brands
$55.83 /

+1.1 (+2.01%)

RIDE Lordstown Motors
$17.70 /

+0.705 (+4.15%)

POWW AMMO
$6.75 /

+0.45 (+7.14%)

NVAX Novavax
$187.62 /

+15.04 (+8.71%)

LB L Brands
$55.83 /

+1.1 (+2.01%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.